Drug Combination Details
| General Information of the Combination (ID: C28568) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Megestrol acetate Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | HepG2 cells were collected in 0.2 ml of PBS, and the cell suspensions were then injected subcutaneously into five-week-old BALB/C male nude mice (5*106 cells per mouse). | |||||
| Experimental
Result(s) |
MA/ATO combined treatment enhanced antitumor efficacy. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells. Exp Ther Med. 2018 Apr;15(4):4047-4055. | |||
